Literature DB >> 28265679

FLAIRfusion Processing with Contrast Inversion : Improving Detection and Reading Time of New Cerebral MS Lesions.

M A Schmidt1, R A Linker2, S Lang3, H Lücking3, T Engelhorn3, S Kloska3, M Uder4, A Cavallaro4, A Dörfler3, P Dankerl3,4.   

Abstract

PURPOSE: To evaluate the performance of an innovative image processing approach for detection of T2-weighted hyperintense multiple sclerosis (MS) lesions.
METHODS: In this study 20 consecutive patients with inflammatory demyelinating lesions were retrospectively evaluated of whom 10 patients featured progressive disease and 10 a stable lesion load. 3 mm transversal FLAIRfusion imaging was processed and archived. Image processing was performed through landmark-based 3D co-registration of the previous and current isotropic FLAIR examination followed by inversion of image contrast. Thereby, the hyperintense signals of the unchanged MS plaques extinguish each other, while newly developed lesions appear bright on FLAIRfusion. Diagnostic performance was evaluated by 4 experienced readers. Consensus reading supplied the reference standard. Sensitivity, specificity, NPV (negative predictive value), PPV (positive predictive value), interreader agreement and reading time were the outcome measures analyzed.
RESULTS: Combined sensitivity was 100% at a specificity of 88.2%, with PPV ranging from 83.3% to 90.1% and NPV at 100%. Reading time was nearly 5‑fold faster than conventional side by side comparison (35.6 s vs. 163.7 s, p < 0.001). Cohen's kappa was excellent (>0.75; p < 0.001) and Cronbach's alpha was 0.994.
CONCLUSION: FLAIRfusion provides reliable detection of newly developed MS lesions along with strong interreader agreement across all levels of expertise in 35 s of reading time.

Entities:  

Keywords:  FLAIR; Follow-up; Image processing; Multiple sclerosis; T2 lesions

Mesh:

Year:  2017        PMID: 28265679     DOI: 10.1007/s00062-017-0567-y

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


  23 in total

Review 1.  Disease-modifying treatments for progressive multiple sclerosis.

Authors:  Giancarlo Comi
Journal:  Mult Scler       Date:  2013-10       Impact factor: 6.312

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Improving Multiple Sclerosis Plaque Detection Using a Semiautomated Assistive Approach.

Authors:  J van Heerden; D Rawlinson; A M Zhang; R Chakravorty; M A Tacey; P M Desmond; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2015-06-18       Impact factor: 3.825

4.  Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.

Authors:  Bastiaan Moraal; Dominik S Meier; Peter A Poppe; Jeroen J G Geurts; Hugo Vrenken; William M A Jonker; Dirk L Knol; Ronald A van Schijndel; Petra J W Pouwels; Christoph Pohl; Lars Bauer; Rupert Sandbrink; Charles R G Guttmann; Frederik Barkhof
Journal:  Radiology       Date:  2008-11-26       Impact factor: 11.105

5.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

Review 6.  Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging.

Authors:  Daniel García-Lorenzo; Simon Francis; Sridar Narayanan; Douglas L Arnold; D Louis Collins
Journal:  Med Image Anal       Date:  2012-09-29       Impact factor: 8.545

7.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 8.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

9.  Clinical evaluation of semi-automatic landmark-based lesion tracking software for CT-scans.

Authors:  Peter Dankerl; Alexander Cavallaro; Matthias Dietzel; Alexey Tsymbal; Martin Kramer; Sascha Seifert; Michael Uder; Matthias Hammon
Journal:  Cancer Imaging       Date:  2014-04-22       Impact factor: 3.909

10.  Computer-aided assessment of diagnostic images for epidemiological research.

Authors:  Alison G Abraham; Donald D Duncan; Stephen J Gange; Sheila West
Journal:  BMC Med Res Methodol       Date:  2009-11-11       Impact factor: 4.615

View more
  3 in total

1.  Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Authors:  Kianush Karimian-Jazi; Brigitte Wildemann; Ricarda Diem; Daniel Schwarz; Thomas Hielscher; Wolfgang Wick; Martin Bendszus; Michael O Breckwoldt
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-07-16

Review 2.  Navigating choice in multiple sclerosis management.

Authors:  Ralf A Linker; Andrew Chan
Journal:  Neurol Res Pract       Date:  2019-02-28

3.  Scanned versus Fused-Reconstructed Oblique MR-Images for Assessment of the Tibiofibular Syndesmosis-Diagnostic PerFormance and Reader Agreement.

Authors:  Hannes Seuss; Matthias Hammon; Frank Roemer; Rafael Heiss; Rolf Janka; Michael Uder; Peter Dankerl
Journal:  Diagnostics (Basel)       Date:  2021-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.